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ABSTRACT: Background: The most common
genetic risk factor for Parkinson’s disease known is a
damaging variant in the GBA1 gene. The entire GBA1
gene has rarely been studied in a large cohort from a
single population. The objective of this study was to
assess the entire GBA1 gene in Parkinson’s disease
from a single large population.
Methods: The GBA1 gene was assessed in 3402
Dutch Parkinson’s disease patients using next-
generation sequencing. Frequencies were compared
with Dutch controls (n = 655). Family history of
Parkinson’s disease was compared in carriers and
noncarriers.
Results: Fifteen percent of patients had a GBA1 non-
synonymous variant (including missense, frameshift, and
recombinant alleles), compared with 6.4% of controls
(OR, 2.6; P < 0.001). Eighteen novel variants were
detected. Variants previously associated with Gaucher’s
disease were identified in 5.0% of patients compared
with 1.5% of controls (OR, 3.4; P < 0.001). The rarely
reported complex allele p.D140H + p.E326K appears to
likely be a Dutch founder variant, found in 2.4% of
patients and 0.9% of controls (OR, 2.7; P = 0.012). The
number of first-degree relatives (excluding children) with
Parkinson’s disease was higher in p.D140H + p.E326K
carriers (5.6%, 21 of 376) compared with p.E326K car-
riers (2.9%, 29 of 1014); OR, 2.0; P = 0.022, suggestive
of a dose effect for different GBA1 variants.
Conclusions: Dutch Parkinson’s disease patients dis-
play one of the largest frequencies of GBA1 variants
reported so far, consisting in large part of the mild
p.E326K variant and the more severe Dutch p.D140H
+ p.E326K founder allele. © 2020 The Authors. Move-
ment Disorders published by Wiley Periodicals LLC
on behalf of International Parkinson and Movement
Disorder Society.
Key Words: familial aggregation; GBA sequencing;
genetic risk factor; glucocerebrosidase; heredity
The most common genetic risk factor known to date
for Parkinson’s disease (PD) is a damaging variant in
the GBA gene (GBA1), encoding the lysosomal
glucocerebrosidase enzyme.1 To avoid confusion with
the nonlysosomal genes GBA2 and GBA3, the GBA
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
*Correspondence to: Dr. Geert Jan Groeneveld, Zernikedreef 8, 2333
CL, Leiden, The Netherlands; E-mail: ggroeneveld@chdr.nl
Relevant conflicts of interest/financial disclosures: The authors
report no competing interests.
Funding agencies: Genotyping was funded by Lysosomal
Therapeutics, Inc.
[The copyright line for this article was changed on Aug 21, 2020 after
original online publication]
Received: 30 December 2019; Revised: 17 April 2020; Accepted: 1
May 2020
Published online 2 July 2020 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.28112
Movement Disorders, Vol. 35, No. 9, 2020 1667
G B A 1 G E N E S C R E E N I N G I N P A R K I N S O N ’ S D I S E A S E
gene is also referred to as GBA1. In most populations,
4%-12% of PD patients carry a heterozygous GBA1
variant and in Ashkenazi Jewish PD patients this is
approximately 20%.2,3 The risk of PD in GBA1 variant
carriers is increased by an estimated overall 2- to 7-fold
(odds ratios [ORs]).2-5 Rare homozygous or compound
heterozygous GBA1 variants can cause the autosomal-
recessive lysosomal storage disorder Gaucher’s disease
(GD). More than 400 variants have been reported to be
associated with GD,6,7 and all these alleles are potential
risk factors for developing PD.
Full GBA1 gene sequencing is essential to unambigu-
ously identify gene variants, considering a long tail of
rare variants or even population-specific variants.3,4,8
Nevertheless, rarely the entire GBA1 gene has been
sequenced in a large cohort from a single population.
Here, we report such a large-scale GBA1 screening per-
formed in the Netherlands in the framework of a large
program aimed at identifying patients with GBA1 vari-
ants for a clinical trial targeting the GBA1 mechanism.
We sequenced the GBA1 entire open-reading frame
(ORF) in 3402 people with PD living in the Nether-
lands. Variant frequency was compared with an exis-
ting Dutch control cohort (n = 655). Family history of
PD was assessed in a subset of patients with the most
common variants to compare familial aggregation.
Materials and Methods
Participants
PD patients were included in the Netherlands between
April 2017 and March 2018 (see supplementary data for
details). Age at diagnosis of ≤50 years was considered
early onset, and > 50 years was considered late-onset PD.
This study was approved by an independent ethics com-
mittee. Written informed consent was obtained from all
participants according to the Declaration of Helsinki.
An independent Dutch study of 655 patients with
abdominal aortic aneurysms was used for comparison
(see supplementary data), using whole-exome sequencing
(WES) data (average GBA1 coverage was 101 times).
Data regarding the presence of neurological disease were
unavailable.
Genotyping
Saliva was obtained from patients using Oragene DNA
OG-500 tubes (DNA Genotek). DNA isolation, next-
generation sequencing (NGS), and data analysis was per-
formed by GenomeScan B.V., Leiden, the Netherlands.
Primers were selected to unambiguously sequence the func-
tional GBA1 gene and not the pseudogene, using long-
range polymerase chain reaction (PCR). In a post hoc
experimental setup using long-read sequencing with the
PacBio Sequel system, phasing was assessed in 3 samples.
See supplementary material for methodological details,
including validation of a subset using Sanger sequencing.
Historically, GBA1 variants have been described based
on the amino acid position excluding the 39-residue signal
sequence at the start (also known as “allelic nomencla-
ture”). Both the Human Genome Variation Society rec-
ommended nomenclature, and the allelic nomenclature is
given (NCBI Reference Sequence: NM_000157.3). If an
allele contained more than 1 exonic variant, this is
referred to as a complex allele.
Genotypes were classified into 4 categories based on
clinical associations using the Human Gene Mutation
Database7: (1) Gaucher’s disease associated (GD),
(2) Parkinson’s disease associated (PD), (3) synonymous,
or (4) novel. If a subject had both a known and a novel
variant, the genotype was considered novel. See supple-
mentary data for details.
All variants that were 6 nucleotides or closer to a splice
site were assessed with 4 in silico splicing programs
implemented in Alamut (Alamut Visual version 2.13; see
supplementary data).
A 2-step cross-validation was performed to assess risk
of both false-positive and false-negative results when
using WES (see supplementary data).
Family History
All patients with the GBA1 p.D140H + p.E326K, p.
E326K, p.N370S, or p.L444P variants and a random
subset of patients who did not carry GBA1 variants as
per our methods and variant selection criteria (hence-
forth referred to as GBA1 wild type) were given a ques-
tionnaire to assess familial aggregation of PD and to
assess a possible founder location of the p.D140H + p.
E326K complex allele. See supplementary material for
details.
Statistical Analysis
Fisher’s exact test was used for categorical variables
and the Mann-Whitney U test for continuous variables.
Significance was flagged at P < 0.05. ORs were calcu-
lated with a 95% CI. IBM SPSS Statistics 25 software
was used.
Results
In total, 3638 PD patient samples were included, of
which 3402 could be genotyped. Of the remaining
236 samples, no DNA could be extracted or PCR failed.
Demographics can be found in Supplementary Table 1.
Eighty-one percent of patients were recruited through
referral by a neurologist.
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Sequencing
Average coveragewas 2703 times (Supplementary Fig. 1).
The subset of samples used in the Sanger sequencing valida-
tionwere all confirmed (see supplementary data).
GBA1 Variants
All GBA1 exonic and splice-site variants are listed in
Table 1, including frequency comparison between PD
patients and controls. In short, the total PD cohort had
15.0% nonsynonymous variants (including missense,
frameshift, and recombinant alleles) versus 6.4% in
controls (OR, 2.6; 95% CI, 1.9–3.6; P < 0.001). For
GD variants observed in patients (5.0%) versus con-
trols (1.5%), the OR was 3.4 (95% CI, 1.8–6.5;
P < 0.001) and for the PD variants observed in patients
(9.3%) versus controls (4.4%), the OR was 2.2 (95%
CI, 1.5–3.3; P < 0.001).
In total, 19 GD variants, 5 PD variants, 12 synony-
mous variants, and 18 novel variants were identified. In
1 sample with p.D140H + p.E326K, phasing was con-
firmed using PacBio sequencing. See supplementary
data for a further description of variants found. Supple-
mentary Table 3 contains a variant frequency compari-
son with data from GoNL9 and GnomAD10,11 for
reference; however, methodology in these cohorts was
not dedicated to GBA1 sequencing.
No intronic variants were assessed to have a possible
effect on splicing (Supplementary Table 4).
Control Cohorts Cross-Validation
In the control cohort, 42 samples had a nonsynonymous
GBA1 variant detected using WES that could be tested
with our NGS protocol. Using NGS, 4 control samples
were detected to be false-positive, and 3 samples were par-
tially false-negative (for p.D140H in a p.D140H + E326K
complex allele). Conversely, after rerunning 48 GBA-PD
samples with WES, 1 false-negative was detected. See sup-
plementary data for details.
Demographics Based on GBA1 Status
Demographics are given in Supplementary Table 1,
divided over whether subjects carried a nonsynonymous
variant. A larger portion of carriers had early-onset PD
(27.2%) compared with noncarriers (18.2%), P < 0.001.
Conversely, of all subjects with early onset, 20.1% had a
GBA1 variant, compared with 13.1% in those with late
onset (P < 0.001).
GBA Variants and Familial Aggregation of PD
A questionnaire was completed by 180 carriers of
p.E326K, 24 carriers of p.N370S, 28 carriers of p.L444P
(including 4 complex and 3 recombinant alleles), 73 carriers
of p.D140H + p.E326K, and 135 GBA1 wild types. Com-
bining all carriers, 3.6% of all siblings and parents
combined had PD comparedwith 2.0% in siblings and par-
ents of noncarriers (OR, 1.8; 95% CI, 1.0–3.2; P = 0.043).
None of the children developed PD, probably because of
the present younger age, so thesewere excluded from analy-
sis of first-degree relatives (Supplementary Table 2). Supple-
mentary Figure 2 depicts the total number of first-degree
relatives (excluding children) per variant type and the per-
centage of these relatives with PD. A variant dose effect was
seen (see supplementary data for details).
Founder Location p.D140H + p.E326K
Supplementary data and Supplementary Figure 3 show
a heat map of descent of grandparents of p.D140H +
p.E326K carriers, visually suggesting (no formal statistical
testing) the northern Netherlands as a possible founder
location for this complex allele.
Discussion
To our knowledge, this study is the largest cohort
known to date from a single country that has had full
gene GBA1 sequencing in PD patients. A total of
15.0% of all patients had nonsynonymous GBA1 vari-
ants, which is the highest prevalence reported to date in
a non-Ashkenazi Jewish population. The relatively
high prevalence of the population-specific p.D140H +
p.E326K complex allele and the long tail of rare vari-
ants, including 18 novel variants, highlight the impor-
tance of sequencing the full GBA1 ORF. Identifying all
these variants will strengthen our understanding of the
effect of GBA1 variants, and it facilitates recruitment
for the upcoming GBA1-targeted trials, hopefully
resulting in a first disease-modifying drug for PD.12
Comparing different countries,3,4,8,13-26 the p.E326K
variant is reported most frequently in the Netherlands (pre-
sent study) and Scandinavian countries.20,24 Table 2 com-
pares the most commonGBA1 variants and the p.D140H
+ p.E326K complex allele in large PD cohorts from single
countries that performed full GBA1 ORF sequencing.
Swedish24 and Russian15 cohorts were included despite
selective sequencing because of their size to compare the
p.E326K variant. This overview shows the near-exclusive
appearance of p.D140H + p.E326K in the Netherlands.
The p.D140H + p.E326K complex allele has only sporadi-
cally been reported, once in GD,27,28 sporadically in PD4,29
and once in Lewy body dementia.30
Intronic splice-site variants have rarely been systemat-
ically assessed previously,17,23; however, these do not
seem to play a role in GBA-PD pathology in our Dutch
cohort.
The importance of adequate genotyping methodology
when sequencing GBA1 was once more confirmed. In
the control cohort, the GBA1 variants were reassessed
with NGS, which identified 4 false-positive p.L444P
variants in WES. Also, 3 p.D140H variants were falsely
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not identified in 3 samples that also carried the
p.E326K variant. The performance of the hybridization
capture panel was lower over the p.D140H region,
reflected in local lower coverage. Combined with a pos-
sible allelic imbalance for this specific variant, in which
the amplification prefers the wild-type allele over the p.
D140H allele, this could explain the false-negative out-
put. Therefore, caution is advised when using GBA1
data generated using a methodology not specifically
designed for GBA1 sequencing (including databases
like ExAC or gnomAD).
Because the p.E326K and p.T369M variants do not
cause Gaucher’s disease, these have long been termed
polymorphisms. However, it has been shown in meta-
analyses that these variants do confer an increased risk
of developing PD (OR, 1.99 for p.E326K and 1.74 for
p.T369M)31-33 and therefore, despite not causing GD,
should not be considered neutral polymorphisms.
Of all participants diagnosed with PD at 50 years of
age or younger, 20.1% had a GBA1 variant. In clinical
practice, when genetic testing is performed in early-onset
PD, GBA1 is not always included. Because of the high
prevalence of GBA1 variants in early-onset PD, it
deserves consideration to include this in the screening,
although the predictive value of a GBA1 variant for off-
spring is still limited.
GBA1 variant carriers have a larger frequency of a
positive family history for Parkinson’s disease4,5,34
compared with noncarriers. In the current study, car-
riers of p.D140H + p.E326K had significantly more
first-degree relatives with PD compared with p.E326K
carriers. This implies a dose effect of variant severity in
familial aggregation. However, it did not reach statisti-
cal significance for other variant types, likely because of
the rarity of these variants.
The current study has some limitations. Because our
NGS method used short-read sequencing, phasing of mul-
tiple variants could not be determined, unless these were
within approximately 500 base pairs of each other. How-
ever, for a single p.D140H + p.E326K sample phasing
was confirmed using PacBio, and p.D140H was never
seen without p.E326K. A recombinant gene could be
identified if the long-range PCR resulted in 2 distinct
peaks on the Fragment Analyzer. See supplementary data
for a further discussion of possible limitations.
In conclusion, this study is a successful example of how
to ascertain and genotype a large cohort of patients with
PD within a short time frame, which is relevant for pro-
gressing clinical trials aimed at developing personalized
treatments.
The Dutch PD population appears to have a rela-
tively large number of GBA1 variant carriers, con-
sisting mostly of the mild p.E326K variant and the
likely more severe Dutch p.D140H + p.E326K complex
allele, with a possible founder effect in the northern
part of the Netherlands. In total, 18 novel GBA1
TABLE 2. International comparison of Parkinson’s disease cohorts that performed full GBA1 gene sequencing, sorted based
on total percent of GBA1 variant carriers [Color table can be viewed at wileyonlinelibrary.com]
International comparison of total and common GBA1 variants in Parkinson’s disease cohorts
PD (n) GBA1 (%) E326K T369M N370S L444P D140H + E326K Other
Ashkenazi Jewish 735 18.0 1.6 0 11.8 0.3 0 4.2
This cohort (NL) 3402 15.0 6.7 2.5 0.9 0.6 2.5 1.8
France 1130 12.5 4.2 1.5 2.9 1 0.1 2.7
Colombia 131 12.2 1.5 0 2.3 2.3 0 6.1
Norway 442 12.0 6.6 3.6 0.2 1.4 0 0.5
Spain 532 11.7 3 0.9 0.9 2.4 0 4.3
United States 1369 11.6 5 2.2 1.3 1.2 0.1 1.9
United Kingdom 1893 11.1 4.5 1.8 0.6 1.6 0.1 2.4
Eastern Canada 225 11.1 1.8 4.9 0.9 1.8 0 1.8
Belgium 266 9.8 4.1 1.1 1.1 1.5 0.4 1.5
Japan 534 9.4 0 0 0 4.1 0 5.2
New Zealand 229 9.2 4.8 3.1 0.4 0 0.4 0.9
Sweden 1625 8.3 5.8 N/A 0.4 2.2 N/A N/A
Peru 471 7.2 1.1 0.6 0.2 2.8 0 1.8
Russia 762 6.6 2.4 2.5 0.5 1.1 N/A N/A
Greece 172 6.4 0.6 0 0 1.2 0 4.7
Portugal 230 6.1 0.9 0.9 2.2 1.3 0 0.9
Korea 277 6.1 0 0 0 0.7 0 5.4
North Africa 194 4.6 0.5 1.0 1.0 1.5 0 0.5
PD, Parkinson’s disease; NL, the Netherlands; N/A, not applicable.
All variant frequencies are given in percentages. Sweden and Russia performed selective sequencing. France is a European study, with 89% of subjects from
France. North Africa is primarily Algeria, but also Morocco, Tunisia, and Libya. References: Ashkenazi Jewish (1), Netherlands (current study), France (2), Colombia
(3), Norway (4), Spain (5), United States (6), United Kingdom (7), eastern Canada (8), Belgium (9), Japan (10), New Zealand (11), Sweden (12), Peru (3), Russia (13),
Greece (14), Portugal (15), Korea (16), and north Africa (17).
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variants were detected. GBA1 variant carriers had a
younger age at onset and a higher chance of a positive
family history for PD, with a trend toward a dose effect
based on clinical association of the variant.
Acknowledgments: The authors thank all operational personnel for
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Parkinson’s disease patient association (Parkinson Vereniging) and all par-
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